dc.contributor.author | Batırel, Ayşe | |
dc.contributor.author | Güçlü, Ertuǧrul | |
dc.contributor.author | Arslan, Ferhat | |
dc.contributor.author | Koçak, Funda | |
dc.contributor.author | Karabay, Oğuz | |
dc.contributor.author | Özer, Serdar | |
dc.contributor.author | Turanlı, Münevver | |
dc.contributor.author | Mert, Ali | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:35:52Z | |
dc.date.available | 10.07.201910:49:14 | |
dc.date.available | 2019-07-10T19:35:52Z | |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Batırel, A., Güçlü, E., Arslan, F., Koçak, F., Karabay, O., Özer, S., Turanlı, M. ve Mert, A. (2014). Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: A multicenter real-life study. International Journal of Infectious Diseases, 28, 153-159. https://dx.doi.org/10.1016/j.ijid.2014.09.004 | en_US |
dc.identifier.issn | 1201-9712 | |
dc.identifier.uri | https://dx.doi.org/10.1016/j.ijid.2014.09.004 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/974 | |
dc.description.abstract | Objective: To compare responses to tenofovir (TDF) and entecavir (ETV) therapy. Methods: This was a multicenter retrospective study including treatment-naïve patients with chronic hepatitis B (CHB) who received TDF or ETV. The primary end-points were undetectable HBV-DNA at 48 weeks and serological and biochemical responses. Results: Out of 195 CHB patients, 90 (46%) received TDF and 105 (54%) received ETV; 72% were male, their mean age was 43. ±. 12 years, and the mean duration of treatment was 30.2. ±. 15.7 months. Hepatitis B e antigen (HBeAg) seropositivity was 32% in the TDF group and 34% in the ETV group. HBeAg seroconversion rates in HBeAg-positive patients were 24% in the TDF group and 39% in the ETV group; the difference was not significant (. p=. 0.2). The mean time to alanine aminotransferase (ALT) normalization and rates of ALT normalization at 3, 6, 12, 18, and 24 months were similar in the two groups (. p > 0.05). The mean time to undetectable HBV-DNA levels in the TDF and ETV groups was 11.5. ±. 8.9 and 12.9. ±. 10.8 months, respectively (. p=. 0.32). A significantly greater decline in HBV-DNA levels at 12 and 18 months was observed in the TDF group (. p=. 0.02 and p=. 0.03, respectively). Seven (7%) patients on ETV therapy had virological breakthrough (. p=. 0.01). Only one patient in each group had hepatitis B surface antigen (HBsAg) clearance. None of the patients developed decompensation or hepatocellular carcinoma during treatment. Conclusions: The two drugs appear to have similar efficacy in CHB patients. However, 7% of patients on ETV therapy had virological breakthrough, while none of the patients on TDF therapy did. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Unported | * |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/ | * |
dc.subject | Chronic Hepatitis B | en_US |
dc.subject | Entecavir | en_US |
dc.subject | HBV | en_US |
dc.subject | Tenofovir | en_US |
dc.subject | Treatment | en_US |
dc.title | Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: A multicenter real-life study | en_US |
dc.type | article | en_US |
dc.relation.ispartof | International Journal of Infectious Diseases | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-8554-7651 | en_US |
dc.authorid | 0000-0001-8945-2385 | en_US |
dc.identifier.volume | 28 | en_US |
dc.identifier.startpage | 153 | en_US |
dc.identifier.endpage | 159 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1016/j.ijid.2014.09.004 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.identifier.scopusquality | Q1 | en_US |